NEW YORK, March 6, 2026, 08:23 EST
- This week, SEC filings revealed that Kenvue handed out fresh restricted stock unit awards to its senior executives.
- General counsel Matthew Orlando picked up 122,286 units, while Carlos De Jesus, who heads North America, got 127,051.
- Kenvue shares barely budged in U.S. premarket trading Friday.
Kenvue (KVUE.N) has handed out new stock-based awards to top execs, filings show this week. Among them: a block of 122,286 restricted stock units for the general counsel. The consumer health outfit is still awaiting regulatory go-aheads for its planned sale to Kimberly-Clark.
The filings take on extra weight as Kenvue navigates a lengthy, very public run-up to a change of control. During this stretch, investors and employees are watching retention, pay, and leadership stability with sharper focus than usual.
Restricted stock units, or RSUs, represent equity compensation that generally converts to common shares once vested. Kenvue, in separate Form 4s filed March 4, disclosed RSU awards for Group President North America Carlos De Jesus—127,051 units—and Group President APAC Anindya Dasgupta with 98,994 units. Both grants will vest in three equal tranches across 2027, 2028, and 2029.
Kenvue handed Chief Tech & Data Officer Michael Wondrasch 79,407 RSUs, while Group President LATAM Leonardo Curado Gomes de Lemos received 13,234, both following the same three-year vesting plan detailed in filings.
Vice President and Chief Accounting Officer Heather Howlett received a 22,233-unit RSU grant, according to one filing. In a separate trade, 526 common shares were withheld for taxes related to vesting, priced at $18.15 each.
Kenvue ticked up roughly 0.3% to $18.25 in early U.S. trading Friday. Kimberly-Clark (KMB.N) edged higher, too.
Back in November, Kimberly-Clark inked a deal to acquire Kenvue for over $40 billion, eyeing a combination that would bring Huggies and Tylenol together. Both sets of shareholders gave their nod in January. The companies are sticking to a timeline that targets the second half of 2026 for closing, pending regulatory sign-off and a list of standard conditions.
The finish line isn’t straightforward here. Alongside the usual antitrust checks, Kenvue is contending with lawsuits and ongoing questions about product safety and inherited liabilities—issues that have the potential to tangle up approvals, throw off deal timelines, and muddy the financial logic, even if shareholders are on board.
Related articles: NYSE:KVUE
